Effect of odanacatib on BMD and fractures: Estimates from bayesian univariate and bivariate meta-analyses

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3070-3079

  Gajic Veljanoski, Olga ^a   Tomlinson, George ^b,c   Srighanthan, Jeevitha ^a   Adachi, Jonathan D ^d   Josse, Robert ^c,e   Brown, Jacques P ^f   Cheung, Angela M ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ODANACATIB; PLACEBO; BIPHENYL DERIVATIVE; CATHEPSIN K; CTSK PROTEIN, HUMAN;

BAYES THEOREM; BIVARIATE ANALYSIS; BONE DENSITY; DRUG EFFECT; DRUG EFFICACY; FEMUR NECK; FRACTURE; HIP; HUMAN; LUMBAR SPINE; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROBABILITY; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNIVARIATE ANALYSIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FRACTURES, BONE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BAYES THEOREM; BIPHENYL COMPOUNDS; BONE DENSITY; CATHEPSIN K; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907201179     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1162     Document Type: Review

References (62)

1. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011; 7(8): 447-456.
2. Papapoulos S, Bone H, Dempster D, et al. Phase 3 fracture trial of odanacatib for osteoporosis-baseline characteristics and study design. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid-8dbc5fc5-2225-4249-8504-d02bb8663d10. Accessed December 2, 2013.
3. Merck Co, Inc. A study of MK-0822 in postmenopausal women with osteoporosis to assess fracture risk (MK-0822-018). http://clinicaltrials. gov/ct2/show/NCT00529373?term-NCT00529373&rank-1 Accessed November 27, 2013.
4. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010; 25(5): 937-947.
5. Cheung AM, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture and estimated bone strength [published online February 12, 2014]. J Bone Miner Res. doi: 10.1002/jbmr.2194.
6. Bonnick S, De Villiers T, Odio A, et al. Effects of odanacatib on BMDand safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebocontrolled trial. J Clin Endocrinol Metab. 2013; 98(12): 4727-4735.
7. Nakamura T, Shiraki M, Fukunaga M, et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-A double-blind, randomized, dose-finding study. Osteoporos Int. 2014; 25(1): 367-376.
8. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013; 98: 571-580.
9. Eisman JA, BoneHG,Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: threeyear continued therapy and resolution of effect. J Bone Miner Res. 2011; 26(2): 242-251.
10. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausalwomenwith low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012; 27: 2251-2258.
11. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook. org. Accessed December 3, 2013.
12. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester, England: John Wiley, Sons, Ltd; 2004.
13. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-Analysis: multivariate approach and meta-regression. Stat Med. 2002; 21: 589-624.
14. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Thompson JR. An evaluation of bivariate random-effects meta-Analysis for the joint synthesis of two correlated outcomes. Stat Med. 2007; 26: 78-97.
15. Jackson D, Riley R, White IR. Multivariate meta-Analysis: potential and promise. Stat Med. 2011; 30: 2481-2498.
16. Berkey CS, HoaglinDC,Antczak-Bouckoms A, Mosteller F, Colditz GA. Meta-Analysis of multiple outcomes by regression with random effects. Stat Med. 1998; 17: 2537-2550.
17. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-Analysis. Stat Med. 1995; 14: 395-411.
18. Nam IS, Mengersen K, Garthwaite P. Multivariate meta-Analysis. Stat Med. 2003; 22: 2309-2333.
19. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-Analysis. J R Stat Soc Ser A Stat Soc. 2009; 172: 137-159.
20. Riley RD. Multivariate meta-Analysis: the effect of ignoring withinstudy correlation. J R Stat Soc Ser A Stat Soc. 2009; 172: 789-811.
21. Gajic-Veljanoski O, Cheung AM, Bayoumi AM, Tomlinson G. The choice of a noninformative prior on between-study variance strongly affects predictions of future treatment effect. Med Decis Making. 2013; 33: 356-368.
22. Spiegelhalter DJ, Abrams KR, Myles JP. Prior distributions. In: Spiegelhalter DJ, Abrams KR, Myles JP, eds. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester, England: John Wiley, Sons, Ltd; 2004: 139-180.
23. Riley RD, Dodd SR, Craig JV, Thompson JR, Williamson PR. Metaanalysis of diagnostic test studies using individual patient data and aggregate data. Stat Med. 2008; 27: 6111-6136.
24. Gajic-Veljanoski O. Quantifying Uncertainty in the Efficacy of Vitamin K on Fractures in Postmenopausal Women: Economic Evaluation, Evidence Synthesis and Bayesian Meta-Analysis. PhD Dissertation, University of Toronto; 2013. http://hdl.handle.net/1807/43583. Accessed Jan 15, 2014.
25. Lunn DJ, Thomas A, Best N, Spiegelhalter D.WinBUGS -A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000; 10: 325-337.
26. Plummer M. JAGS: Just Another Gibbs Sampler. Version 0.8. http://sourceforge.net/projects/mcmc-jags/. Accessed December 2, 2013.
27. Plummer M, Best N, Cowles K, Vines K. CODA: convergence diagnosis and output analysis for MCMC. R News. 2006; 6(1): 7-11.
28. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998; 7: 434-455.
29. De Papp AE, Cheung A, Majumdar S, et al. Effects of odanacatib on the distal radius and tibia in postmenopausal women: improvements in cortical geometry and estimated bone strength. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid-1e016235-b279-4685-Ab67-0b176c840cbd. Accessed December 2, 2013.
30. Keaveny T, Brixen K, Chapurlat R, et al. Odanacatib improved estimated femoral strength in postmenopausal women. Results of a 2-year placebo-controlled trial. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid-40c6b422-7703-49b8-Ad03-63ae4cbf4722. Accessed December 2, 2013.
31. Uchida S, Shiraki M, Fukunaga M, et al. The results of a double-blind, randomized, phase 2 dose-finding study of odanacatib, a potent cathepsin-K inhibitor, in Japanese patients with osteoporosis with a modelbased pharmacokinetic (PK) analysis. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid-42973cf1-376a-4fc7-9629-d489950434de. Accessed December 2, 2013.
32. Engelke K, Fuerst T, Dardzinski B, et al. Femur QCT analysis using MIAF in postmenopausal women treated with odanacatib-results of a 2-year placebo-controlled trial. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx? aid-f0d72632-5a5f-48e5-8c31-102cb0a451b7. Accessed December 2, 2013.
33. De Villiers T, Bonnick S, Odio A, et al. Effects of odanacatib on BMD and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2012; 27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid-7cac73ab-A522-4500-8554-552e73bb7944. Accessed December 2, 2013.
34. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009; 86(2): 175-182.
35. McClung MR, Eisman JA, Bone HG, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 3-year continued therapy and resolution of effect. J Clin Densitom. 2010; 13(1): 133.
36. Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010; 10(6): 452-458.
37. Eisman JA, Binkley N, Bone H, et al. Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: year 4 results. Osteoporos Int. 2011; 22(suppl 4): S526.
38. Denker A, Binkley N, Bone H, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Menopause. 2011; 18(12): 1344.
39. Miller P, Binkley N, Bone H, et al. Four-year results of a phase 2 study of the cathepsin K inhibitor odanacatib in postmenopausal women with low bone mineral density: Effects on bone mineral density and bone turnover markers. Osteoporos Int. 2011; 22(Suppl 2): S426.
40. Badsha H, Binkley N, Bone H, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5-year results of a phase 2 trial. Osteoporos Int. 2011; 22(suppl 5): S691.
41. Binkley N, Bone H, Gilchrist N, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Int Med J. 2012; 42(suppl 1): 28.
42. McClung M, Binkley N, Bone H, et al.BMDresponse in the odanacatib phase 2 trial: prespecified threshold and subgroup analyses. Endocr Rev. 2012; 33 (03-MeetingAbstracts): OR08-2.
43. Nakamura T, Shiraki M, Fukunaga M, et al. A double-blind, randomized, dose-finding, phase 2 study of odanacatib, a potent cathepsin-K inhibitor, in Japanese patients with osteoporosis. Osteoporos Int. 2012; 23(Suppl 2): S237.
44. Brixen K, Chapurlat R, Cheung AM, et al. Imaging and finite element analysis of the spine and hip following 2 years of treatment with odanacatib in postmenopausal women. Osteoporos Int. 2012; 23(Suppl 2): S62.
45. Resch H, Binkley N, Bone H, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Osteoporos Int. 2012; 23(Suppl 2): S61.
46. Stoch SA, Zajic S, Stone JA, et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: Safety, tolerability, pharmacokinetics and pharmacodynamics-results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. 2013; 75(5): 1240-1254.
47. Smith E, Chapurlat R, Bonnick S, et al. Effects of odanacatib on BMD and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate. Int Med J. 2013; 43(suppl 2): 29.
48. Leung A, Petrovic R, DaSilva C, Rosenberg E, Santora A, Lombardi A. Effect of odanacatib on bone density and bone turnover markers in postmenopausal women with low bone mineral density: Year 4 results. Reumatol Clin. 2011; 7 (Suppl 1): 170.
49. Miller P, Binkley N, Bone H, et al. Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial. Osteoporos Int. 2012; 23(Suppl 3): S456.
50. Chapurlat R, Bonnick S, De Villiers T, et al. Effects of odanacatib on BMD and overall safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate. Arthritis Rheum. 2012; 64(10): S312.
51. Chapurlat R, Brixen K, Cheung AM, et al. Effects of odanacatib on the distal radius and tibia in postmenopausal women: Improvements in cortical geometry and estimated bone strength. Arthritis Rheum. 2012; 64(10): S844.
52. Uemura N, Willmer JP, Nakamichi N, et al. Safety, pharmacokinetics and pharmacodynamics (bone turnover) of odanacatib: two double-blind, randomized, placebo-controlled phase I studies in Japanese men and postmenopausal women. In: Proceedings from the American Society for Clinical Pharmacology and Therapeutics; March 5-9, 2013; Indianapolis, IN. Abstract S88.
53. Cranney A, Wells G, Willan A, et al. Meta-Analyses of therapies for postmenopausal osteoporosis. II. Meta-Analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002; 23: 508-516.
54. Cranney A, Tugwell P, Adachi J, et al. Meta-Analyses of therapies for postmenopausal osteoporosis. III. Meta-Analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002; 23: 517-523.
55. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.NEngl J Med. 2007; 356: 1809-1822.
56. Mackey DC, Black DM, Bauer DC, et al. Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res. 2011; 26: 2411-2418.
57. Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebralnonhip fractures in osteoporosis: a network meta-Analysis. Semin Arthritis Rheum. 2011; 40: 275-284.e1-e2.
58. Black DM, Schafer AL. The search for the optimal anabolic osteoporosis therapy. J Bone Miner Res. 2013; 28: 2263-2265.
59. Ng KW. Potential role of odanacatib in the treatment of osteoporosis. Clin Interv Aging. 2012; 7: 235-247.
60. Khosla S. Odanacatib: location and timing are everything. J Bone Miner Res. 2012; 27: 506-508.
61. Cheung AM, Brixen K, Chapurlat R, Keaveny T, Majumdar S, De Papp A. Imaging and finite element analysis of the spine, hip, radius, and tibia following 2 years of treatment with odanacatib in postmenopausal women. J Clin Densitom. 2013; 16(3): 263.
62. Update on phase III trial for odanacatib, Merck's investigational Cat-K inhibitor for osteoporosis. http://www.mercknewsroom.com/pressrelease/research-development-news/update-phase-iii-Trial-odanacatibmercks-investigational-cat. Whitehouse Station, NJ: Merck & Co, Inc. Published July 11, 2012. Accessed December 2, 2013.